| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Cyanidin 3-xyloside does not have a single defined pharmacological target but acts through multiple mechanisms including antioxidant activity and anti-inflammatory pathways. Its mode of action involves potent antioxidant activity, where it scavenges free radicals and reduces oxidative stress in living organisms. As an anthocyanin, it may interact with various cellular signaling pathways involved in inflammation, cell survival, and cardiovascular function.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Cyanidin 3-xyloside exhibits potent antioxidant and anti-inflammatory properties. It scavenges free radicals and reduces oxidative stress. Among anthocyanins, cyanidin 3-xyloside possesses radical scavenging activity, though the strength of this activity may be influenced by the sugar unit linked to the anthocyanidin. Detailed in vitro activity data, including IC50 values for antioxidant assays, are not extensively documented.
|
| ln Vivo |
In vivo activity of Cyanidin 3-xyloside is inferred from its antioxidant and anti-inflammatory properties. Its antioxidant properties make it a subject of interest for developing strategies targeting chronic diseases linked to oxidative stress, such as cardiovascular diseases and certain cancers. Detailed in vivo efficacy data from animal models are not extensively documented in the available literature.
|
| Enzyme Assay |
The in vitro antioxidant assay for Cyanidin 3-xyloside typically involves measuring its ability to scavenge free radicals using DPPH, ABTS, or FRAP assays. The compound is incubated with the radical-generating system, and the reduction in radical concentration is measured spectrophotometrically. Anti-inflammatory activity may be assessed by measuring inhibition of pro-inflammatory cytokine production in stimulated immune cells. Standard protocols include appropriate positive controls such as ascorbic acid or Trolox.
|
| Cell Assay |
In vitro cell-based assays for Cyanidin 3-xyloside are conducted using various cell lines to evaluate its antioxidant and anti-inflammatory effects. Cells are treated with the compound and exposed to oxidative stress or inflammatory stimuli. Oxidative stress markers such as reactive oxygen species, lipid peroxidation, and glutathione levels are measured. Inflammatory cytokine production is assessed by ELISA. Cell viability is evaluated using MTT or similar assays.
|
| Animal Protocol |
In vivo animal studies for Cyanidin 3-xyloside would typically be conducted using models of oxidative stress, inflammation, cardiovascular disease, or cancer. Animals would be administered the compound via oral or intraperitoneal routes, and efficacy would be evaluated by measuring oxidative stress markers, inflammatory markers, and disease-specific outcomes. However, detailed in vivo protocols and efficacy data are not available from the search results.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cyanidin 3-xyloside include a molecular weight of 454.81 and a molecular formula of C20H19O10Cl. As a glycosylated anthocyanin, it may have limited oral bioavailability due to poor absorption and extensive metabolism. The compound is intended for research use only. Detailed pharmacokinetic parameters are not extensively documented in the available literature.
|
| Toxicity/Toxicokinetics |
Toxicity information for Cyanidin 3-xyloside is limited. As a naturally occurring anthocyanin found in foods, it is generally considered to have low toxicity. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
Cyanidin 3-xyloside is a naturally occurring anthocyanin composed of cyanidin linked to xylose at the 3-position. It exhibits potent antioxidant and anti-inflammatory properties with potential cardiovascular and anti-cancer benefits. It has MW 454.81 and formula C20H19O10Cl. It is intended for research use only.
|
| Molecular Formula |
C20H19CLO10
|
|---|---|
| Molecular Weight |
454.81
|
| Exact Mass |
454.067
|
| CAS # |
29761-24-8
|
| PubChem CID |
71315022
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.261
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
31
|
| Complexity |
578
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1[C@H]([C@@H](C(C(O1)OC2=CC3=C(C=C(C=C3[O+]=C2C4=CC(=C(C=C4)O)O)O)O)O)O)O.[Cl-]
|
| InChi Key |
ORTBMTXABUAMJS-CRTITRSXSA-N
|
| InChi Code |
InChI=1S/C20H18O10.ClH/c21-9-4-12(23)10-6-16(30-20-18(27)17(26)14(25)7-28-20)19(29-15(10)5-9)8-1-2-11(22)13(24)3-8;/h1-6,14,17-18,20,25-27H,7H2,(H3-,21,22,23,24);1H/t14-,17+,18?,20?;/m1./s1
|
| Chemical Name |
(4S,5R)-2-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromenylium-3-yl]oxyoxane-3,4,5-triol;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1987 mL | 10.9936 mL | 21.9872 mL | |
| 5 mM | 0.4397 mL | 2.1987 mL | 4.3974 mL | |
| 10 mM | 0.2199 mL | 1.0994 mL | 2.1987 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
